Intervir Therapeutics Overview
- Founded
-
2013
- Status
-
Private
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
1
Intervir Therapeutics General Information
Description
Developer of drugs intended to treat viral diseases. The company's drugs are discovered to treat viral diseases using structure action relationships (SAR) that inhibit virus-host interactions required for egress and spread of infectious virus from the cell, enabling doctors to treat diseases caused by filoviruses (Ebola and Marburg), arenaviruses (Lassa Fever and Junín), influenza A virus and rhabdoviruses (rabies).
Contact Information
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
- 3160 Chestnut Street
- Suite 200
- Philadelphia, PA 19104
- United States
+1 (610) 000-0000
Intervir Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Accelerator/Incubator | 01-Aug-2015 | Completed | Startup |
Intervir Therapeutics Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Mike Saporito | Chief Executive Officer & President |
Intervir Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| UPstart (Philadelphia) | Accelerator/Incubator | 000 0000 | 000000 0 |